Skip to main content
S&P 5007,562.96-0.30%DOW51,663.08-0.83%NASDAQ26,015.57+0.13%BTC$75,791.00+0.23%ETH$2,402.19+0.32%GOLD$4,342.30+0.22%OIL$102.35-3.29%
Smart Investors Daily
Sumitomo Pharma Co., Ltd. logo

OTC · SMDPY

Sumitomo Pharma Co., Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$10.45

Up+$0.00 (+0.00%)

Updated Sep 16, 2026, 6:57 PM

SID Score

6.0/10

Composite research score

Smart Money

46/100

Neutral

Market cap
4.55B
P/E ratio
5.76
Dividend yield
0.00%
52-week range
— – —
Volume
1K
Avg. volume
17

Price performance

SMDPY price history

1M range · 0 trading sessions · Daily adjusted prices

SMDPY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SMDPY news

The latest Smart Investors Daily articles mentioning SMDPY.

Stock researchCompany · Overview

SMDPY research

Overview

Company profile and research snapshot.

Company profile

SUMITOMO PHARMA CO U/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.40
Implied upside
—
Analysts
11
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 10, 2026

2026 Assessment of the Nuvisertib Market: Sales Forecasts, Clinical Differentiation, Competitive Threats, and Commercial Opportunities Through 2034

Nuvisertib targets unmet needs in relapsed/refractory myelofibrosis with differentiated, potentially disease-modifying activity. Combination therapy, expansion into other cancers and expedited regulatory pathways offer additional opportunities.Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Nuvisertib Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering. Nuvisertib (TP-3654) is an investigational, orally administered, highly selective PIM1 kinase i

Yahoo · Sep 4, 2026

Sumitomo Pharma (TSE:4506) Stock Looks Below Fair Value On Earnings Power

Sumitomo Pharma stock has delivered a very large 3 year gain but the broader valuation checks still suggest the shares trade on the cheap side compared with the fundamentals. After a weak year to date performance, the recent rebound raises the question of whether the stock still prices in too much caution or if expectations are finally catching up. Over the past 3 years, Sumitomo Pharma is up about 228.5% which signals a major re rating by the market over that window. The key support for the...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By